Kyndryl Holdings, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Kyndryl Holdings, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $15.06B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $16.05B | Feb 17, 2026 |
| FY2025 | Mar 31, 2023 | $17.03B | Feb 17, 2026 |
| FY2024 | Mar 31, 2022 | $4.43B | May 30, 2024 |
| FY2024 | Dec 31, 2021 | $18.66B | May 30, 2024 |
| FY2024 | Mar 31, 2021 | $4.77B | May 30, 2024 |
| FY2023 | Dec 31, 2020 | $19.35B | May 26, 2023 |
| FY2021 | Dec 31, 2019 | $20.28B | Mar 10, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $49.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $58.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2023 | $79.00M | Feb 17, 2026 |
| FY2024 | Mar 31, 2022 | $23.00M | May 30, 2024 |
| FY2024 | Dec 31, 2021 | $63.00M | May 30, 2024 |
| FY2023 | Dec 31, 2020 | $76.00M | May 26, 2023 |
| FY2021 | Dec 31, 2019 | $83.00M | Mar 10, 2022 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $2.59B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $2.77B | Feb 17, 2026 |
| FY2025 | Mar 31, 2023 | $2.91B | Feb 17, 2026 |
| FY2024 | Mar 31, 2022 | $690.00M | May 30, 2024 |
| FY2024 | Dec 31, 2021 | $2.78B | May 30, 2024 |
| FY2024 | Mar 31, 2021 | $714.00M | May 30, 2024 |
| FY2023 | Dec 31, 2020 | $2.95B | May 26, 2023 |
| FY2021 | Dec 31, 2019 | $2.97B | Mar 10, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $942.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $454.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2023 | $781.00M | Feb 17, 2026 |
| FY2024 | Mar 31, 2022 | $189.00M | May 30, 2024 |
| FY2024 | Dec 31, 2021 | ($119.00M) | May 30, 2024 |
| FY2024 | Mar 31, 2021 | ($328.00M) | May 30, 2024 |
| FY2023 | Dec 31, 2020 | $628.00M | May 26, 2023 |
| FY2021 | Dec 31, 2019 | $1.13B | Mar 10, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $752.00M | Mar 10, 2022 |
| FY2021 | Dec 31, 2020 | $1.04B | Mar 10, 2022 |
| FY2021 | Dec 31, 2019 | $1.19B | Mar 10, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $10.45B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $10.59B | Feb 17, 2026 |
| FY2024 | Mar 31, 2023 | $11.46B | May 30, 2024 |
| FY2023 | Mar 31, 2022 | $13.44B | May 26, 2023 |
| FY2023 | Dec 31, 2021 | $13.21B | May 26, 2023 |
| FY2021 | Dec 31, 2020 | $11.21B | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $9.12B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $9.47B | Feb 17, 2026 |
| FY2024 | Mar 31, 2023 | $10.00B | May 30, 2024 |
| FY2023 | Mar 31, 2022 | $10.73B | May 26, 2023 |
| FY2023 | Dec 31, 2021 | $10.45B | May 26, 2023 |
| FY2021 | Dec 31, 2020 | $6.27B | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.22B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $1.02B | Feb 17, 2026 |
| FY2024 | Mar 31, 2023 | $1.37B | May 30, 2024 |
| FY2023 | Mar 31, 2022 | $2.62B | May 26, 2023 |
| FY2023 | Dec 31, 2021 | $2.77B | May 26, 2023 |
| FY2021 | Dec 31, 2020 | $4.87B | Mar 10, 2022 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $790.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $805.00M | Feb 17, 2026 |
| FY2025 | Mar 31, 2023 | $812.00M | Feb 17, 2026 |
| FY2024 | Mar 31, 2022 | $823.00M | May 30, 2024 |
| FY2023 | Dec 31, 2021 | $732.00M | May 26, 2023 |
| FY2023 | Dec 31, 2020 | $1.23B | May 26, 2023 |
| FY2021 | Dec 31, 2019 | $1.16B | Mar 10, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | ($2.07B) | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | ($2.32B) | Feb 17, 2026 |
| FY2024 | Mar 31, 2023 | ($1.98B) | May 30, 2024 |
| FY2023 | Mar 31, 2022 | ($605.00M) | May 26, 2023 |
| FY2023 | Dec 31, 2021 | ($375.00M) | May 26, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | $1.79B | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | $1.55B | Feb 17, 2026 |
| FY2024 | Mar 31, 2023 | $1.85B | May 30, 2024 |
| FY2023 | Mar 31, 2022 | $2.13B | May 26, 2023 |
| FY2023 | Dec 31, 2021 | $2.22B | May 26, 2023 |
| FY2021 | Dec 31, 2020 | $24.00M | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 1 | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | (1) | Feb 17, 2026 |
| FY2025 | Mar 31, 2023 | (6) | Feb 17, 2026 |
| FY2024 | Mar 31, 2022 | (1) | May 30, 2024 |
| FY2024 | Dec 31, 2021 | (10) | May 30, 2024 |
| FY2024 | Mar 31, 2021 | (2) | May 30, 2024 |
| FY2023 | Dec 31, 2020 | (8) | May 26, 2023 |
| FY2021 | Dec 31, 2019 | (4) | Mar 10, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | 1 | Feb 17, 2026 |
| FY2025 | Mar 31, 2024 | (1) | Feb 17, 2026 |
| FY2025 | Mar 31, 2023 | (6) | Feb 17, 2026 |
| FY2024 | Mar 31, 2022 | (1) | May 30, 2024 |
| FY2024 | Dec 31, 2021 | (10) | May 30, 2024 |
| FY2024 | Mar 31, 2021 | (2) | May 30, 2024 |
| FY2023 | Dec 31, 2020 | (8) | May 26, 2023 |
| FY2021 | Dec 31, 2019 | (4) | Mar 10, 2022 |